Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10

D. D. Ankola, E. W. Durbin, G. A. Buxton, J. Schaefer, U. Bakowsky, M. N. V. Ravi Kumar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Combination therapy will soon become a reality, particularly for those patients requiring poly-therapy to treat co-existing disease states. This becomes all the more important with the increasing cost, time and complexity of the drug discovery process prompting one to look at new delivery systems to increase the efficacy, safety and patient compliance of existing drugs. Along this line, we attempted to design nano-scale systems for simultaneous encapsulation of cyclosporine A (CsA) and coenzyme Q10 (CoQ10) and model their encapsulation and release kinetics. The in vitro characterization of the co-encapsulated nanoparticles revealed that the surfactant nature, concentration, external phase volume, droplet size reduction method and drug loading concentration can all influence the overall performance of the nanoparticles. The semi-quantitative solubility study indicates the strong influence of CoQ10 on CsA entrapment which was thought to be due to an increase in the lipophilicity of the overall system. The in vitro dissolution profile indicates the influence of CoQ10 on CsA release (64%) to that of individual particles of CsA, where the release is faster and higher (86%) on 18th day. The attempts to model the encapsulation and release kinetics were successful, offering a possibility to use such models leading to high throughput screening of drugs and their nature, alone or in combination for a particular polymer, if chi-parameters are understood.

LanguageEnglish
Pages065104
Number of pages11
JournalNanotechnology
Volume21
Issue number6
DOIs
Publication statusPublished - 11 Jan 2010

Fingerprint

coenzyme Q10
Coenzymes
Encapsulation
Cyclosporine
Nanoparticles
Kinetics
Pharmaceutical Preparations
Screening
Dissolution
Surface active agents
Solubility
Throughput
Surface-Active Agents
Polymers
Costs

Keywords

  • PLGA nanoparticles
  • drug-delivery
  • oral delivery
  • ellagic acid
  • microparticles
  • release
  • bioavailability
  • nephrotoxicity
  • formulations
  • prediction

Cite this

Ankola, D. D. ; Durbin, E. W. ; Buxton, G. A. ; Schaefer, J. ; Bakowsky, U. ; Kumar, M. N. V. Ravi. / Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10. In: Nanotechnology. 2010 ; Vol. 21, No. 6. pp. 065104.
@article{632244b9a62b48018ae752af20324e44,
title = "Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10",
abstract = "Combination therapy will soon become a reality, particularly for those patients requiring poly-therapy to treat co-existing disease states. This becomes all the more important with the increasing cost, time and complexity of the drug discovery process prompting one to look at new delivery systems to increase the efficacy, safety and patient compliance of existing drugs. Along this line, we attempted to design nano-scale systems for simultaneous encapsulation of cyclosporine A (CsA) and coenzyme Q10 (CoQ10) and model their encapsulation and release kinetics. The in vitro characterization of the co-encapsulated nanoparticles revealed that the surfactant nature, concentration, external phase volume, droplet size reduction method and drug loading concentration can all influence the overall performance of the nanoparticles. The semi-quantitative solubility study indicates the strong influence of CoQ10 on CsA entrapment which was thought to be due to an increase in the lipophilicity of the overall system. The in vitro dissolution profile indicates the influence of CoQ10 on CsA release (64{\%}) to that of individual particles of CsA, where the release is faster and higher (86{\%}) on 18th day. The attempts to model the encapsulation and release kinetics were successful, offering a possibility to use such models leading to high throughput screening of drugs and their nature, alone or in combination for a particular polymer, if chi-parameters are understood.",
keywords = "PLGA nanoparticles, drug-delivery, oral delivery, ellagic acid, microparticles, release, bioavailability, nephrotoxicity, formulations, prediction",
author = "Ankola, {D. D.} and Durbin, {E. W.} and Buxton, {G. A.} and J. Schaefer and U. Bakowsky and Kumar, {M. N. V. Ravi}",
year = "2010",
month = "1",
day = "11",
doi = "10.1088/0957-4484/21/6/065104",
language = "English",
volume = "21",
pages = "065104",
journal = "Nanotechnology",
issn = "0957-4484",
number = "6",

}

Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10. / Ankola, D. D.; Durbin, E. W.; Buxton, G. A.; Schaefer, J.; Bakowsky, U.; Kumar, M. N. V. Ravi.

In: Nanotechnology, Vol. 21, No. 6, 11.01.2010, p. 065104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10

AU - Ankola, D. D.

AU - Durbin, E. W.

AU - Buxton, G. A.

AU - Schaefer, J.

AU - Bakowsky, U.

AU - Kumar, M. N. V. Ravi

PY - 2010/1/11

Y1 - 2010/1/11

N2 - Combination therapy will soon become a reality, particularly for those patients requiring poly-therapy to treat co-existing disease states. This becomes all the more important with the increasing cost, time and complexity of the drug discovery process prompting one to look at new delivery systems to increase the efficacy, safety and patient compliance of existing drugs. Along this line, we attempted to design nano-scale systems for simultaneous encapsulation of cyclosporine A (CsA) and coenzyme Q10 (CoQ10) and model their encapsulation and release kinetics. The in vitro characterization of the co-encapsulated nanoparticles revealed that the surfactant nature, concentration, external phase volume, droplet size reduction method and drug loading concentration can all influence the overall performance of the nanoparticles. The semi-quantitative solubility study indicates the strong influence of CoQ10 on CsA entrapment which was thought to be due to an increase in the lipophilicity of the overall system. The in vitro dissolution profile indicates the influence of CoQ10 on CsA release (64%) to that of individual particles of CsA, where the release is faster and higher (86%) on 18th day. The attempts to model the encapsulation and release kinetics were successful, offering a possibility to use such models leading to high throughput screening of drugs and their nature, alone or in combination for a particular polymer, if chi-parameters are understood.

AB - Combination therapy will soon become a reality, particularly for those patients requiring poly-therapy to treat co-existing disease states. This becomes all the more important with the increasing cost, time and complexity of the drug discovery process prompting one to look at new delivery systems to increase the efficacy, safety and patient compliance of existing drugs. Along this line, we attempted to design nano-scale systems for simultaneous encapsulation of cyclosporine A (CsA) and coenzyme Q10 (CoQ10) and model their encapsulation and release kinetics. The in vitro characterization of the co-encapsulated nanoparticles revealed that the surfactant nature, concentration, external phase volume, droplet size reduction method and drug loading concentration can all influence the overall performance of the nanoparticles. The semi-quantitative solubility study indicates the strong influence of CoQ10 on CsA entrapment which was thought to be due to an increase in the lipophilicity of the overall system. The in vitro dissolution profile indicates the influence of CoQ10 on CsA release (64%) to that of individual particles of CsA, where the release is faster and higher (86%) on 18th day. The attempts to model the encapsulation and release kinetics were successful, offering a possibility to use such models leading to high throughput screening of drugs and their nature, alone or in combination for a particular polymer, if chi-parameters are understood.

KW - PLGA nanoparticles

KW - drug-delivery

KW - oral delivery

KW - ellagic acid

KW - microparticles

KW - release

KW - bioavailability

KW - nephrotoxicity

KW - formulations

KW - prediction

UR - http://www.scopus.com/inward/record.url?scp=77949408219&partnerID=8YFLogxK

U2 - 10.1088/0957-4484/21/6/065104

DO - 10.1088/0957-4484/21/6/065104

M3 - Article

VL - 21

SP - 065104

JO - Nanotechnology

T2 - Nanotechnology

JF - Nanotechnology

SN - 0957-4484

IS - 6

ER -